Histone deacetylase (HDAC) inhibitors cause growth arrest at the G1 and/or G2/M phases, and induce differentiation and/or apoptosis in a wide variety of tumour cells. The growth arrest at G1 phase by HDAC inhibitors is thought to be highly dependent on the upregulation of p21/WAF1, but the precise mechanism by which HDAC inhibitors cause G2/M arrest or apoptosis in tumour cells is unknown. Gadd45 causes cell cycle arrest at the G2/M phase transition and participates in genotoxic stress-induced apoptosis. We show here that it is also induced by a typical HDAC inhibitor, trichostatin A (TSA), through its promoter, in a p53-independent manner. To identify the mechanism of activation of the gadd45 promoter, we performed luciferase reporter analyses and electrophoretic mobility shift assays. These revealed that both the Oct-1 and CCAAT sites are needed for the full activation by TSA. We also found that the transcription factors Oct-1 and NF-Y specifically bind to each site. Thus, HDAC inhibitors can induce Gadd45 through its promoter without the need for functional p53, and both the Oct-1 and NF-Y concertedly participate in TSA-induced activation of the gadd45 promoter.
Introduction
Progress has been made in understanding the regulation of gene transcription by acetylation of histones. Thus, hyperacetylation of histones by histone acetyltransferases (HATs) and hypoacetylation of histones by histone deacetylases (HDACs) have been implicated in transcriptional activation and repression (Struhl, 1998) . Moreover, inappropriate chromatin modification by HATs or HDACs may be closely associated with the development of tumours (Archer and Hodin, 1999) .
On the other hand, numerous in vivo and in vitro studies have revealed that HDAC inhibitors are potent inducers of growth arrest at both the G1 and G2/ M phases (Yoshida and Beppu, 1988) , and induce differentiation and/or apoptotic cell death of various types of tumour cell lines (Marks et al., 2000) . Derivatives of butyric acid, SAHA, MS-275 and FK228, all of which are capable of acting as HDAC inhibitors, are currently undergoing clinical trials (Kramer et al., 2001) . The effect of p53 on cell growth and apoptosis may be modulated through its deacetylation by an HDAC1-containing complex (Luo et al., 2000) . Therefore, modulating the transcriptional activity of p53 may be involved in the growth arrest and apoptosis induced by HDAC inhibitors. However, HDAC inhibitors also exert antitumour effects in p53-deficient cell lines (Saito et al., 1999) , indicating that there is a p53-independent pathway in such cells.
We previously focused on the effect of growth inhibition by HDAC inhibitors, and found that HDAC inhibitors (butyrate, trichostatin A (TSA) and SAHA) induce the p21/WAF1 expression through its promoter Sp1 sites in a p53-independent fashion Sowa et al., 1997; Huang et al., 2000) . p21/WAF1 is known to exert pRB-dependent growth arrest mainly in the G1 phase as a cyclin-CDK inhibitor (Harper et al., 1995) , and the growth arrest at G1 phase by HDAC inhibitors may be highly dependent on the upregulation of p21/WAF1. Despite this pivotal role of the p21/ WAF1 induction in the G1 growth arrest by HDAC inhibitors, whether this leads to cell cycle arrest at the G2/M phase or to apoptosis by HDAC inhibitors is currently unclear. Therefore, we have continued to search for the mechanisms that underlie these effects of HDAC inhibitors, using MG63 human osteosarcoma cells lacking p53 (Chandar et al., 1992) . We have found that Gadd45 is also induced by HDAC inhibitors such as TSA and sodium butyrate.
The Gadd45 gene is one of several growth-arrest and DNA-damage-inducible genes, which was originally cloned from Chinese hamster cell lines in which it is rapidly induced by UV radiation (Fornace et al., 1988) . It is induced by various DNA-damaging agents and by p53 through the third intron of the gene (Kastan et al., 1992) . The exact function of Gadd45 remains unclear, but in many studies it has been shown to cause G2/M arrest Zhan et al., 1999) , and it may be involved in apoptosis (Takekawa and Saito, 1998; Harkin et al., 1999; Zhang et al., 2001) and in DNA repair and genomic stability Smith et al., 2000) . Importantly, Gadd45 may have antioncogenic effects as a downstream molecule of p53 and BRCA1 (Kastan et al., 1992; Harkin et al., 1999; Jin et al., 2000; Li et al., 2000; Smith et al., 2000; Mullan et al., 2001) . In this report, we investigated how Gadd45 may be induced by HDAC inhibitors. Elucidating the mechanism that underlies the upregulation of target genes in tumour cells by HDAC inhibitors may provide a clue to the antitumour effects of such inhibitors, and may demonstrate the feasibility of using them as a strategy for gene-regulating chemoprevention and chemotherapy (Sakai, 1996; Sowa and Sakai, 2000) .
Results

TSA blocks cell growth at the G1 and G2/M phases of MG63 human osteosarcoma cells
We first examined the effect of TSA on the proliferation of MG63 cells. A dose-dependent inhibition of the cell growth was observed as described previously . To examine the cell cycle behaviour, logphase proliferating MG63 cells were incubated in the absence or presence of various concentrations of TSA for 24 h, processed for FACSCalibur flow cytometry (Becton Dickinson, Inc., Franklin Lakes, NJ, USA), and analysed. As shown in Figure 1 , the percentage of cells in the S phase decreased from 40% in medium alone to 5% in 2.0 mM TSA. Cells at the G1 phase increased from 51% in medium alone to 62% in 1.0 mM TSA. Cells at the G2/M phase dramatically increased from 9% in medium alone to 56% in 2.0 mM TSA, and also accumulated at both G1 and G2/M phases. These data show that TSA induces both G1 and G2/M arrest in MG63 cells through a p53-independent pathway, because p53 is inactivated in MG63 cells (Chandar et al., 1992) .
TSA causes an increase in gadd45 mRNA and protein levels, leading to G2/M cell cycle arrest in MG63 cells
To clarify the potential involvement of Gadd45 underlying the G2/M arrest of MG63 cells by HDAC inhibitors, we ascertained whether Gadd45 is induced by TSA. Western blot analysis showed that both Gadd45 and p21/WAF1 proteins increased with 1.0 mM TSA treatment and more markedly with 2.0 mM ( Figure 2a ). Next, we performed Northern blot analysis to confirm that the upregulation of Gadd45 is caused by an increase in mRNA. As shown in Figure 2b , treatment of MG63 cells with TSA resulted in a concentrationdependent increase in gadd45 mRNA levels. Timecourse studies showed that gadd45 mRNA started to induce at 6 h after the treatment with 2.0 mM TSA, gradually increased, and then disappeared at 48 h ( Figure 2c ). These results indicate that TSA induces the production of the Gadd45 protein via upregulation of mRNA transcription.
To address the contribution of the Gadd45 expression to the increase in the G2/M population, a GADD45-IRES-EGFP plasmid, which permits both the enhanced green fluorescent protein (eGFP) gene and the gadd45 gene to be translated, was transiently transfected into MG63 cells, and cell cycle dynamics were analysed 48 h after transfection using FACSCalibur flow cytometry (Becton Dickinson). MG63 cells expressing exogenous Gadd45 were selected as the GFP-positive cells using an analytical gate, and the DNA contents were analysed. As shown in Figure 3a , 7% of the cells at the G2/M phase were in the GFP-negative cells, and 8% of the cells were not transfected with plasmid (indicated as Mock). In contrast, those at the G2/ M phase among the GFP-positive cells increased up to 23%. These results suggest a possible role for Gadd45 expression in inducing cell cycle arrest at the G2/M phase. Similarly, an antisense-GADD45-IRES-EGFP (AS-GADD45-IRES-EGFP) plasmid was utilized to explore the contribution of Gadd45 upregulation by TSA to the increase in G2/M arrest. MG63 cells were transiently transfected with AS-GADD45-IRES-EGFP or IRES-EGFP plasmid and treated with 2.0 mM TSA 36 h after transfection, then analysed by FACSCalibur. Analytically gated GFP-positive cells were analysed for DNA contents, and the cells that were assumed to be at the G1 or G2/M phase were counted. As shown in Figure 3b , in contrast with the control plasmid (IRES-EGFP) transfection, the ratio of the population at G2/M phase to G1 phase that expressed antisense Gadd45 was greatly reduced. Taken together, these results suggest that the G2/M cell cycle arrest induced by TSA results from the upregulation of Gadd45 production.
Analysis of the TSA-responsive elements in the gadd45 promoter
To determine whether the level of gadd45 mRNA is increased as a consequence of transcriptional upregulation, and to assess which region of the gadd45 promoter is responsible for TSA stimulation, we analysed the promoter activity of the gadd45 gene. We generated a The fold induction of each plasmid was calculated relative to that of the control vector and represented as 'relative fold induction', because the relative luciferase activity from the vector itself was increased several-fold by TSA. The luciferase activity from pG45-luc was increased about 25-fold (data not shown). As shown in Figure 4 , deletion up to À128 bp relative to the transcription start site (pG45À128) did not reduce the response to TSA. However, with progressive 5 0 deletions, the response to TSA was reduced with deletion of the region between À128 and À81 bp by approximately 80%, and almost disappeared by deletion of the region between À81 and À10 bp, with a further reduction in the response of about 80%. Interestingly, both regions, from À128 to À81 bp and from À81 to À10 bp, contain Oct-1 and CCAAT sites, which have been reported to be conserved between species (Hollander et al., 1993) . Therefore, these regions are believed to be essential for the activation of gadd45 by TSA.
Both Oct-1 and CCAAT sites contribute to the activation of the gadd45 promoter by TSA To test the hypothesis that the Oct-1 and CCAAT sites are essential for activation by TSA, we used three approaches: internal deletion and point mutation analyses of the gadd45 promoter, and mutational analysis of the minimal responsive promoter. In the internal deletion mutant study, we constructed two kinds of internal deletion mutants, both of which lacked each set of Oct-1 and CCAAT sites. Internal deletion between À100 and À76 bp or À81 and À10 bp reduced the response to TSA by about 50-75%. These data suggest that each set of Oct-1 and CCAAT sites is important for the activation by TSA (Figure 5a ). To ascertain which consensus site is more critical for the response, reporter constructs containing point mutations of each site were used for analysis. As shown in Figure 5b , reporter constructs containing mutations at the Oct-1 site, positioned between À75 and À62 bp, and/or containing mutation at the CCAAT box, positioned between À55 and À46 bp, in pG45À81 (pG45À81/mOct1, pG45À81/mOmC, pG45À81/ mCAT, respectively) were generated. The mutation of the Oct-1 site (pG45À81/mOct1) reduced its response by approximately 90%, and the mutation of the CCAAT box (pG45À81/mCAT) also reduced its response by approximately 90%. These data show that both the Oct-1 site and the CCAAT box are involved in activation by TSA. To confirm that both the Oct-1 and CCAAT sites are adequate to activate the promoter, and to determine which site is more important for the response to TSA, we generated two tandem copies of the sequences corresponding to À75 to À42 bp, with and without mutations of the Oct-1 site and/or the CCAAT box, and inserted them into a luciferase reporter plasmid containing a minimal IL-8 promoter. Interestingly, the tandem copy construct, termed IL-8-[OC(D)] 2 , showed a robust response to TSA, and the response was reduced with mutation of either consensus site by approximately 80% (Figure 5c ). These results indicate that both the Oct-1 site and the CCAAT box are responsive to TSA.
Oct-1 and NF-Y bind to the Oct-1 and CCAAT sites of the gadd45 promoter
To determine whether Oct-1 can interact with the Oct-1 consensus site and which protein can interact with the CCAAT box of the gadd45 promoter, we performed electrophoretic mobility shift assays (EMSAs). We used the region positioned between À75 and À42 bp that contains the Oct-1 and CCAAT sites for the probe, named OC-D (Figure 6a ). As shown in Figure 6b , two major DNA-protein complexes were detected, which were eliminated by an excess of unlabelled homologous oligonucleotide (lanes 1, 2). To distinguish one from another, two oligonucleotides, which carried a point mutation either in the Oct-1 site or the CCAAT box, were used as competitors (Figure 6a ). The fastermigrating complex was eliminated by the Oct-1-mutated competitor, mOC-D, and the slower-migrating complex was eliminated by the CCAAT-mutated competitor, OmC-D (Figure 6b, lanes 3, 4) , suggesting that nuclear proteins can bind to the Oct-1 site and the CCAAT box in the OC-D probe. To confirm that the slowermigrating band, which was detected by the mOC-D Figure 4 Deletion analysis of the gadd45 promoter was performed in MG63 cells. Various 5 0 deletion mutants of pG45-luc (luciferase reporter plasmid containing 2.5 kbp of the gadd45 promoter) were transiently transfected into MG63 cells, and luciferase activities were analysed after 24 h of treatment with 2.0 mM TSA. Each of the raw light units (RLU) in cell lysate was standardized to the concentrations of protein. Each-fold induction by TSA was calculated relative to that of the control vector pGVB2 p53-independent induction of Gadd45 by HDAC inhibitor T Hirose et al competition, was truly an Oct-1-containing complex, we performed supershift assays using an antiOct-1 antibody. As shown in Figure 6b and c, the slower-migrating band detected by the mOC-D competition (lane 3 in Figure 6b and lane 2 in Figure 6c ) was supershifted by the addition of anti-Oct-1 antibody (lane 6 in Figure 6b and lane 3 in Figure 6c ). These results demonstrate that the transcription factor Oct-1 can bind to the Oct-1 site of the gadd45 promoter.
On the other hand, according to the survey of NF-Y binding CCAAT boxes by Mantovani et al., the sequence between À56 and À42 bp of the gadd45 promoter is incomplete for interaction with NF-Y (Mantovani, 1998) , and several different transcription factors are known to bind to the CCAAT box, such as NF-Y, C/EBP, CTF/NF-I, CDP and others (Mantovani, 1999) . To verify which transcription factor binds to the CCAAT box, we performed competition studies and supershift analyses. In the competition experiment, unlabelled oligonucleotides carrying the CCAAT box that had been reported to bind to NF-Y or CTF/NF-I, termed NF-Ywild or NF-Iwild, respectively (Inoue et al., 1999) , and OmC-D competitors were used ( Figure 6a ). As shown in Figure 6d , the fastermigrating complex was eliminated by the addition of NF-Ywild but not NF-Iwild (lanes 4, 5). To confirm this result, we performed a supershift assay using anti-NF-Y antibodies. We used anti-NF-YA, anti-NF-YB and anti-C/EBPb antibodies for the supershift experiments, because NF-Y is composed of three subunits, NF-YA, NF-YB and NF-YC. As shown in Figure 6e , the fastermigrating complex was not affected by anti-C/EBPb antibody (lanes 9-11), but the band almost disappeared when using 200 ng of anti-NF-YA antibody (lane 3) and completely disappeared with 500 and 1000 ng of NF-YA antibody (lanes 4, 5). The band was supershifted by anti-NF-YB antibody (lane 6), and the supershifted band became dominant depending on the relative amounts of anti-NF-YB antibody (lanes 7, 8). These results suggested that the anti-NF-YA antibody interferes with the interaction between NF-Y and the OC-D probe, whereas the anti-NF-YB antibody can bind to the complex. According to a previous study on the ability of NF-Y subunits to interact with DNA, the three subunits, NF-YA, -YB and -YC, are all required for DNA binding. Furthermore, direct sequence-specific interactions with this trimer have been shown to be made by NF-YA (Mantovani, 1999) . These reports suggest that our results of EMSAs are compatible with the binding of NF-Y to the CCAAT box of the gadd45 promoter. Finally, we conclude that Oct-1 and NF-Y bind to the Oct-1 site and the CCAAT box mapped at the region from À75 to À42 bp of the gadd45 promoter.
The results suggested that Oct-1 and NF-Y play a crucial role in the TSA-induced activation of the gadd45 promoter. Next, we focused on the mechanisms that underlie the regulation of the promoter by these transcription factors. To investigate whether TSA would mediate the DNA binding ability or the amount of transcription factors Oct-1 and NF-Y, we performed EMSAs using nuclear extracts prepared from either TSA-treated or untreated MG63 cells, and the DNA affinity of each transcription factor was determined. However, EMSAs showed that TSA treatment did not Figure 5 Both the Oct-1 and CCAAT sites of the gadd45 promoter are critical regions for its activation by HDAC inhibitors. Various constructs of luciferase-reporter plasmids were used to identify the TSA-responsive elements. Schematic representations of each construct of the consensus sites and the mutants are indicated below. (a) Internal deletion analysis of the gadd45 promoter. Two constructs of internal deletion of the gadd45 promoter were used for analysis. (b) Mutation analysis of the gadd45 promoter. pG45-81 reporter plasmids harbouring mutations in the Oct-1 site and/or mutations in the CCAAT boxes were used for analysis. (c) Mutation analysis of the minimal responsive promoter. Oligonucleotides containing two tandem copies of the Oct-1 and CCAAT sequences, which are located at the region from À75 to À42 bp, were integrated into the luciferase reporter construct harbouring IL-8 minimal promoter p53-independent induction of Gadd45 by HDAC inhibitor T Hirose et al 11) . Increasing amounts of anti-NF-YA, anti-NF-YB and anti-C/EBPb antibodies were used for supershift assays (200 ng, lanes 3, 6, 9; 500 ng, lanes 4, 7, 10; 1 mg, lanes 5, 8, 11). (f) Effect of TSA treatment on the formation of the complexes. Nuclear extracts from MG63 cells with (lanes 4-6) or without 2.0 mM TSA (lanes 1-3) were used for the assay. Nuclear extracts were incubated with the OC-D probe in the absence (lanes 1, 4) or in the presence of various unlabelled oligonucleotides (lanes 2, 3, 5, 6) p53-independent induction of Gadd45 by HDAC inhibitor T Hirose et al cause any alteration in the DNA affinity of both Oct-1 and NF-Y (Figure 6f ). Therefore, other mechanisms such as post-translational modification of the factors might be important for the stimulation of the gadd45 promoter by TSA.
Oct-1 interacts with SMRT in vivo
Based on these findings, we then performed immunoprecipitation assays to evaluate the links between HDACs and Oct-1 or NF-Y, because TSA is a specific Figure 6 Continued p53-independent induction of Gadd45 by HDAC inhibitor T Hirose et al HDAC inhibitor, and this function may contribute to the upregulation of the gadd45 promoter. According to a recent study on transcriptional regulation of Oct-1, a silencing mediator for retinoid and thyroid hormone receptors (SMRT) interacts with Oct-1 and acts as a transcriptional repressor (Kakizawa et al., 2001 ). Therefore, we evaluated whether SMRT can interact with Oct-1 in MG63 cells. The nuclear extract was immunoprecipitated with anti-Oct-1 antibody, anti-SMRT antibody or anti-NF-YA antibody. Then, the presence of Oct-1 in each immunoprecipitate was determined by Western blot analysis using an anti-Oct-1 antibody.
As expected, Oct-1 was immunoprecipitated with the Oct-1 antibody, and Oct-1 coimmunoprecipitated with the SMRT antibody but not with anti-NF-Y, confirming that the endogenous Oct-1 and SMRT are associated in vivo but that Oct-1 and NF-Y are not ( Figure 7 ).
Discussion
We previously reported the ability of HDAC inhibitors such as butyrate, TSA and SAHA to activate the p21/ WAF1 promoter through Sp1 sites Sowa et al., 1997; Huang et al., 2000) , and the present analysis using human osteosarcoma cells lacking p53 revealed that Gadd45 is also induced by TSA. Although butyrate was also found to activate the transcription of Gadd45 in millimolar concentrations (data not shown), we used TSA for the analysis of Gadd45 induction by HDAC inhibitor, because TSA is a potent and specific inhibitor of HDACs (Yoshida et al., 1990; Finnin et al., 1999) . Two recent reports are consistent with our results. One used DNA array analysis on HT29 p53-negative colon carcinoma cells (Della-Ragione et al., 2001) and the other studied the effects of kinase inhibitors and HDAC inhibitors using SW620 human colon carcinoma cells (Chen et al., 2002) . Although both of these studies showed that the mRNA of the gadd45 gene was induced by butyrate and TSA, both the functional significance and the mechanism of Gadd45 upregulation by HDAC inhibitors were not examined. Besides, it has been suggested that protein kinases are involved in the HDAC inhibitor-induced transcriptional activation of several other promoters (Espinos et al., 1999; Yang et al., 2001) . We ascertained the effect of protein kinase inhibitor on the TSA induced-transcriptional effects and found that the upregulation of gadd45 promoter by TSA is blocked by H7, an inhibitor of serine/threonine protein kinases (data not shown). The factors underlying this inhibition remain to be established. Various genotoxic and nongenotoxic agents have been suggested to induce Gadd45, and both p53-dependent and independent pathways have been suggested to exist for this regulation. Gadd45 is transcriptionally upregulated by p53 via a p53 consensus-binding site in the third intron of the gadd45 gene, and it has been shown to be regulated in a p53-independent manner. Our analysis of the gadd45 promoter, which lacks a p53 consensus-binding site, and EMSA studies using p53-mutated human osteosarcoma MG63 cells showed that Oct-1 and NF-Y were involved in the activation by TSA. Interestingly, consensus sites of these transcription factors mapping at the region from À128 to À40 bp of the gadd45 promoter are conserved among humans, hamsters and mice (Hollander et al., 1993) . In addition, according to recent reports on the p53-independent induction of Gadd45 by BRCA1, MMS and UV radiation, these conserved regions may be important for activation of the gadd45 promoter (Jin et al., 2000 (Jin et al., , 2001 Takahashi et al., 2001) . These conserved regions may be critical for p53-independent transcriptional regulation of the gadd45 gene, and the involvement of HDAC with these conserved regions may have important implications for the regulation of the gadd45 gene in wild-type cells lacking p53.
We performed EMSAs to determine whether alteration of DNA binding with Oct-1 or NF-Y may contribute to the activation of the promoter; however, TSA treatment did not cause any alteration in such binding (Figure 6f ). We further examined the interaction of these transcription factors with DNA by controlling the amount of cold competitors to detect minor changes; however, the DNA binding to these transcription factors did not seem to be altered by TSA treatment. Therefore, we explored the mechanisms that underlie the transcriptional activation of Oct-1 and NF-Y by HDAC inhibitors.
Oct-1 has a repressive effect in certain promoters (Schwachtgen et al., 1998) . Kakizawa et al. (2001) have also demonstrated that the POU domain of Oct-1 can interact with SMRT, which is known to be a corepressor associated with HDACs. Therefore, we confirmed the interaction between Oct-1 and SMRT using immunoprecipitation, because TSA might act as an inhibitor of this complex. Indeed, Oct-1 was coimmunoprecipiated by anti-FLAG antibodies in human embryonic kidney (HEK) 293 cells that express FLAG-tagged HDAC1 stably (data not shown). We also examined whether immunoprecipitated Oct-1 was acetylated, using antibodies that can recognize acetylated lysine, because there still remained a possibility that the transcriptional activation of Oct-1 was regulated through acetylation. However, acetylation of Oct-1 was not observed (data not shown). These data suggest that Oct-1 may recruit the HDAC1 complex to the gadd45 promoter through interaction with SMRT and that TSA may inhibit the Figure 7 In vivo association between Oct-1 and SMRT proteins. Nuclear extracts from MG63 cells were immunoprecipitated with anti-Oct-1, anti-SMRT and anti-NF-YA antibodies. The input and immunocomplexes were fractioned by SDS-PAGE, and the presence of Oct-1 was determined by Western blot analysis p53-independent induction of Gadd45 by HDAC inhibitor T Hirose et al repressive effect of this complex for transcription of Gadd45.
On the other hand, at least five recent reports have shown that HDAC inhibitors can activate NF-Ydependent promoters, such as MDR1, HSP70, SHP-1, DNA topoisomerase IIa and the TGFb-type II receptor (Mantovani, 1999; Adachi et al., 2000; Xu et al., 2001; Park et al., 2002) . However, these reports did not establish a direct link between HDACs and NF-Y, and the precise mechanism for the effect of HDAC inhibitors on NF-Y is uncertain. We surmise that interaction between NF-Y and HDACs may account for the activation of NF-Y-dependent promoters by HDAC inhibitors, but an immunoprecipitation study did not indicate any interaction between NF-Y and HDAC1 or SMRT (data not shown). Further study is thus required to understand the mechanisms that underlie the activation of NF-Y-dependent promoters by HDAC inhibitors.
Our luciferase-reporter assay analysis of the point mutation suggested that both the Oct-1 and CCAAT sites appeared to be needed for the transcriptional activation of Gadd45 by HDAC inhibitors. The necessity of both consensus sites for the activation may explain why HDAC inhibitors specifically affect the gadd45 promoter. Interestingly, two tandem copies of the Oct-1 and CCAAT sites, which lie between À75 and À42 bp, showed a dramatic stimulation (about 45-fold induction) by HDAC inhibitors. Moreover, the induction was greatly reduced by generating a point mutation of each consensus site. These results imply that the Oct-1 and CCAAT sites are both necessary and sufficient for the response of HDAC inhibitors, and that Oct-1 and NF-Y appear to cooperate in transcriptional activation by the HDAC inhibitor. It is worth mentioning that point mutations at both the Oct-1 and CCAAT sites of the Gadd45 promoter result in decreased basal transcriptional activity, suggesting that the transcriptional activity of both Oct-1 and NF-Y may be partially repressed by HDACs, at least in the case of the gadd45 promoter. To ascertain whether the interaction between Oct-1 and NF-Y is attributed to the cooperative activation, we performed an immunoprecipitation study. However, the interaction of Oct-1 with NF-Y was not observed (Figure 7) . The state of histone acetylation may be determined by the balance between competing effects of HATs and HDACs. NF-Y has been shown to interact with coactivators known as HATs, such as PC4, hGCN5, p300 and P/CAF (Mantovani, 1999) . In the gadd45 promoter, the Oct-1 site and the CCAAT box are adjacent, and transcription may be regulated by an interplay between the repressive effect of SMRT recruited by Oct-1 and the positive effect of HATs recruited by NF-Y.
The Gadd45 protein may have roles in cell cycle regulation, apoptosis, DNA repair and genomic stability. Thus, Gadd45 causes G2/M arrest through interaction with Cdc2 . The involvement of Gadd45 in apoptosis has also been suggested, and Gadd45 itself is insufficient to induce apoptosis, whereas it was found to sensitize the cells to DNA damage-induced apoptosis (Zhang et al., 2001) . On the other hand, according to a recent study of mouse cells lacking p53, p21/WAF1 and/or gadd45 genes, Gadd45 was suggested to have a role in DNA repair and, importantly, it was suggested that p21/WAF1 and Gadd45 may coordinately participate in a DNA damage response and that these responses may have a major role in the p53 pathway .
Activation of the cell cycle checkpoint is suggested to provide a significant means for cancer therapy (Blagosklonny and Pardee, 2001) . Several in vitro and in vivo studies have revealed the efficacy of imposing different artificial checkpoints by combining drugs in various tumour cells (Li et al., 1999) . From this point of view, HDAC inhibitors may provide significant options for cancer therapy and chemoprevention because they behave as activators both at G1 and G2/M checkpoints by induction of p21/WAF1 and Gadd45, respectively (Sakai, 1996) .
Materials and methods
Cell culture
MG63, a human osteosarcoma cell line, was kindly provided by Dr Y Yanase of Wakayama Medical College. MG63 contains rearrangements in the p53 gene (Chandar et al., 1992) . MG63 cells were maintained in DMEM supplemented with 10% FBS and 4 mM glutamine in a humidified atmosphere of 5% CO 2 in air at 371C.
Cell cycle analysis
Unsynchronized cells were exposed to the agent for 24 h and harvested from culture dishes. After washing with PBS, the cells were fixed in 70% ethanol, treated with RNase A, and the nuclei were stained with propidium iodide (PI) before the DNA content was measured using FACSCalibur (Becton Dickinson, Inc., Franklin Lakes, NJ, USA). Between 10 000 and 60 000 events were collected for each experiment. The ModFit LT V2.0 software package (Verity Software, Topsham, ME, USA) was used to analyse the data. For flow cytometric analysis of eGFP expression, the cells were fixed with 0.1% formaldehyde in PBS for 3 h, treated with RNase A and stained with PI for 12 h. Expression of the eGFP fluorescence was detected by the FL1 (530/30) bandpass filter.
Northern blot analysis
Total RNA was isolated from MG63 cells using the Trizol RNA isolation kit (Invitrogen, Co., Carlsbad, CA, USA), according to the manufacturer's instructions; 10 mg aliquots of total RNA were examined by electrophoresis, transferred to a membrane, and hybridized with a 32 P-labelled XbaI/HindIII fragment from pCMV-45 (a kind gift from Dr AJ Fornace Jr). The same filter was rehybridized with a 32 P-labelled glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA probe for the internal control. The mRNA level was determined using a bio-imaging analyser BAS 2000 (Fujix, Inc., Tokyo, Japan).
Nuclear extraction and Western blot analysis
Nuclear extraction for EMSAs was performed essentially according to the protocol in Molecular Cloning (Sambrook p53-independent induction of Gadd45 by HDAC inhibitor T Hirose et al Chandar and Russel, 2001) . In Western blot analyses, the general procedure outlined by Dignam et al. (1983) was followed. In all, 20 mg of each nuclear extract was loaded onto polyacrylamide gel. The transferred polyvinylidene fluoride (PVDF) membranes were probed with antibodies specific for Gadd45, Oct-1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and antibody specific for p21/WAF1 (Becton Dickinson), and an antibody specific for a-tublin (Oncogene research products, San Diego, CA, USA). Signals were detected by an ECL Western blot analysis system (Amersham Biosciences, Buckinghamshire, UK).
Construction of plasmid DNA
The constructions of the human gadd45 promoter-luciferase fusion plasmid, pG45-luc, deleted pG45À81, pG45À10 were described previously (Takahashi et al., 2001) . To generate pG45À128, complementary pairs of synthesized oligonucleotides corresponding to the sequence between À128 and À81 bp relative to the transcription start site were annealed and then inserted into pG45À81. Likewise, pG45À40 was generated by the insertion of oligonucleotides corresponding to the sequence between À40 and À10 bp into pG45À10. pG45À81/À10 was generated by digesting pG45-luc with BalI, ApaI and blunted, then religated. pG45À100/À76 was constructed by digesting pG45-luc with BalI, and disintegrated by Mung Bean Nuclease, end-filled with a Klenow fragment and religated. To generate several two-copy tandem-repeat constructs including downstream Oct-1 and CCAAT sites between À75 and À42 bp (Figure 5c ), complementary pairs of synthesized oligonucleotides were annealed, phosphorylated, and inserted into IL-8-mini Luc, a kind gift from Dr H Kojima (Kojima et al., 1999) To generate GADD45-IRES-EGFP or AS-GADD45-IRES-EGFP, a gadd45 coding fragment flanked by XbaI and HindIII from pCMV-45 was blunted and inserted into pIRES2-EGFP at a multiple cloning site in either sense or antisense orientation. pIRES2-EGFP was purchased from Clontech (Palo Alto, CA, USA).
Site-directed mutagenesis
The QuickChange site-directed mutagenesis kit (Stratagene Cloning Systems, Co., La Jolla, CA, USA) was used to generate point mutations at the Oct-1 and/or the CCAAT site of the pG45-81 reporter plasmids. The primer used to mutate the Oct-1 site at the region between À75 and À62 bp of the pG45-luc was 5 0 -CCAATGGCCAAGCTGCATG-CAAGCGAGGCGGAAGGTGGTTGG-3 0 (the mutated nucleotides are underlined). pG45-81/mOct1 was generated by digestion of the mutated construct with BalI and MluI, and religated. pG45À81/mCAT and pG45À81/mOmC were constructed from pG45À81 and pG45À81/mOct1 plasmids, respectively. The primer used to mutate the CCAAT site at the region between À55 and À46 bp was 5 0 -GAGGCGG-AAGGTGGTTTTATGAGGGTTGGCAGGATAACCC-3 0 (the mutated nucleotides are underlined).
DNA transfection and luciferase assay
MG63 cells (5 Â 10 4 cells) were seeded in 12-well dishes, and 1.0 mg. per dish of reporter plasmid DNA was transfected using a CellPhect transfection kit (Amersham Biosciences). After 24 h incubation, the cells were treated with the medium containing reagents, and 48 h after the transfection, the cells were collected for luciferase assay. This was performed as described previously (Takahashi et al., 2001) , and the activity was determined as luminescence units normalized for the amount of protein in the cell lysates. All the luciferase assays were carried out in triplicate and each assay was performed at least three times: consistent results were obtained. For flow cytometric analysis of IRES-eGFP, 4 mg of each expression vector was transfected into the cells using the LipofectAMINE PLUS or Lipofectamine 2000 reagent according to the manufacturer's instructions (Invitrogen).
Electrophoretic mobility shift assay
Annealed oligonucleotides containing the sequence between À75 and À42 bp were labelled with [a-32 P]dCTP and used as a probe, termed OC-D. The other oligonucleotides used as competitors are described in Figure 6a . Nuclear extract (7 mg) was incubated for 20 min at 41C in a 20 ml reaction volume containing the appropriate buffer and 1 mg of poly dI-dC. Following preincubation, 32 P-end-labelled probe was added and the reaction mixture was incubated for an additional 20 min at 41C. Competition analyses were performed by mixing fourfold amounts of various unlabelled nucleotides with the reaction mixture containing nuclear extracts prior to the addition of the probe. In supershift experiments, antibodies against Oct-1, NF-YA, NF-YB and C/EBPb (Santa Cruz Biotechnology) were preincubated with nuclear extracts on ice for 1 h before the addition of the probe.
Immunoprecipitation
Nuclear extract (600 mg) was diluted in 600 ml of resuspension buffer (Sambrook and Russel, 2001) . After an overnight incubation of the nuclear extracts with each antibody, the immunocomplex was captured by a 3 h reaction with washed protein A sepharose beads, collected by centrifugation, washed and suspended in 60 ml of sample buffer; 20 ml was prepared and loaded for SDS-PAGE. The following antibodies were used for immunoprecipitation: anti-Oct-1 antibody (Upstate Biotechnology, Inc., Charlottesville, VA, USA), anti-NF-YA antibody and anti-SMRT antibody (Santa Cruz Biotechnology).
